[go: up one dir, main page]

BRPI0509927A - composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina - Google Patents

composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina

Info

Publication number
BRPI0509927A
BRPI0509927A BRPI0509927-7A BRPI0509927A BRPI0509927A BR PI0509927 A BRPI0509927 A BR PI0509927A BR PI0509927 A BRPI0509927 A BR PI0509927A BR PI0509927 A BRPI0509927 A BR PI0509927A
Authority
BR
Brazil
Prior art keywords
composition
antisense oligonucleotide
matter
therapeutically effective
effective combination
Prior art date
Application number
BRPI0509927-7A
Other languages
English (en)
Inventor
Bharvin Kumar Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0509927A publication Critical patent/BRPI0509927A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO FARMACêUTICA, USO DE UMA COMPOSIçãO DE MATéRIA, E, USO DE UMA COMBINAçãO TERAPEUTICAMENTE EFICAZ DE UM OLIGONUCLEOTìDEO ANTI-SENTIDO DE SURVIVINA E CLORIDRATO DE GEMCITABINA. A presente invenção diz respeito a um método de tratar o câncer em um paciente compreendendo a administração de uma quantidade eficaz de um oligonucleotídeo anti-sentido de Survivina em combinação com uma quantidade eficaz de um agente anti-cancerígeno adicional.
BRPI0509927-7A 2004-04-22 2005-04-15 composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina BRPI0509927A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56454004P 2004-04-22 2004-04-22
PCT/US2005/012968 WO2005107771A2 (en) 2004-04-22 2005-04-15 Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0509927A true BRPI0509927A (pt) 2007-09-25

Family

ID=35094133

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509927-7A BRPI0509927A (pt) 2004-04-22 2005-04-15 composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina

Country Status (17)

Country Link
US (3) US20070244065A1 (pt)
EP (3) EP1763356B1 (pt)
JP (1) JP2007533742A (pt)
CN (2) CN101683355A (pt)
AT (2) ATE401088T1 (pt)
AU (1) AU2005240020B2 (pt)
BR (1) BRPI0509927A (pt)
CA (1) CA2562750A1 (pt)
CY (2) CY1110440T1 (pt)
DE (1) DE602005008241D1 (pt)
DK (2) DK1763356T3 (pt)
ES (2) ES2376484T3 (pt)
MX (1) MXPA06012132A (pt)
PL (2) PL1763356T3 (pt)
PT (2) PT1913947E (pt)
SI (2) SI1913947T1 (pt)
WO (1) WO2005107771A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266453A1 (en) * 2008-07-03 2018-01-10 Mayo Foundation for Medical Education and Research Treating cancer
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
CA2952424C (en) 2014-06-16 2019-07-23 Mayo Foundation For Medical Education And Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018045238A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
AU2017324335A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Methods of treating PD-L1 expressing cancer
AU2017324947A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3156667A1 (en) * 2019-10-02 2021-04-08 Sirnaomics, Inc. OLIGONUCLEOTIDES INCLUDING NUCLEOSIDE ANALOGS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
MXPA05008319A (es) * 2003-02-10 2006-02-28 Santaris Pharma As Compuestos oligomericos para la modulacion de la expresion de survivina.

Also Published As

Publication number Publication date
PT1913947E (pt) 2012-01-19
US20120022140A1 (en) 2012-01-26
WO2005107771A2 (en) 2005-11-17
EP1763356B1 (en) 2008-07-16
DK1763356T3 (da) 2008-10-13
CN101683355A (zh) 2010-03-31
EP2145626A1 (en) 2010-01-20
DE602005008241D1 (de) 2008-08-28
CY1112397T1 (el) 2015-12-09
ATE538800T1 (de) 2012-01-15
CY1110440T1 (el) 2015-04-29
MXPA06012132A (es) 2007-01-17
SI1913947T1 (sl) 2012-02-29
JP2007533742A (ja) 2007-11-22
AU2005240020B2 (en) 2011-02-10
CN1950094A (zh) 2007-04-18
WO2005107771A3 (en) 2006-06-08
EP1913947B1 (en) 2011-12-28
PL1763356T3 (pl) 2008-12-31
ES2376484T3 (es) 2012-03-14
SI1763356T1 (sl) 2008-12-31
AU2005240020A1 (en) 2005-11-17
DK1913947T3 (da) 2012-02-06
ES2308488T3 (es) 2008-12-01
US20070244065A1 (en) 2007-10-18
EP1763356A2 (en) 2007-03-21
US20090247611A1 (en) 2009-10-01
EP1913947A1 (en) 2008-04-23
CA2562750A1 (en) 2005-11-17
PL1913947T3 (pl) 2012-05-31
ATE401088T1 (de) 2008-08-15
PT1763356E (pt) 2008-09-05

Similar Documents

Publication Publication Date Title
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
BRPI0912411A8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
MX358617B (es) Formulaciones de inhibidores de dpp iv.
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
SV2008002958A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania referencia cruzada ref. prd2592sv
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
FR2866885B1 (fr) Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
BRPI0416870A (pt) composições anticáncer sinergìticas
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
BR0316021A (pt) Comibinação compreendendo um inibidor de cdk e cisplatina
IL197769A (en) The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication
SE0203817D0 (sv) New composition
BR0316029A (pt) Combinação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.